ArticleMedicine2026
Association of maternal immunoglobulin G levels with pregnancy outcomes in primary immunodeficiency: A retrospective single-center study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregnancy management in women with primary immunodeficiencies (PIDs) is an increasing clinical focus due to improved life expectancy. However, evidence guiding optimal maternal immunoglobulin G (IgG) levels to ensure favorable outcomes is limited, with no consensus on therapeutic targets. This study aimed to evaluate the association between maternal IgG levels, both preconceptionally and during the third trimester, and pregnancy outcomes in women with PIDs. We conducted a retrospective, single-center study reviewing medical records of 25 pregnancies in 18 women with a confirmed PID diagnosis. Key clinical and immunological parameters were analyzed. Associations between maternal serum IgG levels (measured preconceptionally and in the third trimester) and maternal, obstetric, and neonatal outcomes were assessed. A third-trimester IgG threshold of 1000 mg/dL was used for risk stratification analysis. The live birth rate was 80%. Pregnancies resulting in live birth were associated with significantly higher preconceptional IgG levels (median 1090.0 vs 421.0 mg/dL, P = .002) and a longer duration since PID diagnosis (median 62.0 vs 12.0 months, P = .007). The primary finding was that third-trimester IgG levels below 1000 mg/dL were strongly associated with an increased rate of maternal infections (55.6% vs 0.0%; odds ratio 27.5, 95% CI: 1.21-625.41; P = .008). No clear statistical association was found between IgG levels and most neonatal outcomes, including preterm birth or low birth weight. Third-trimester maternal IgG levels are a strong predictor of infection risk during pregnancy in women with PID. Additionally, higher preconceptional IgG levels are associated with successful live births, highlighting the importance of pre-pregnancy immune optimization. Although these findings from a small, retrospective cohort are hypothesis-generating, the 1000 mg/dL IgG threshold appears to be a promising signal for clinical risk stratification. Our results suggest that vigilant monitoring and individualized IgG therapy are crucial for optimizing outcomes in these high-risk pregnancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.